BRAF and neoplasm: However, given that the BRAF p.K483E mutation is present at the high allelic frequency in the patient’s tumor (>40 %), it has previously been described in chronic lymphocytic leukemia and is catalogued in the COSMIC database suggests that BRAF p.K483E may paradoxically result in downstream pathway activation [59].